INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTGN

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves claims that Vistagen and certain officers and/or directors engaged in securities fraud [2]. - Investors who purchased Vistagen securities during the Class Period can request to be appointed as Lead Plaintiff by March 16, 2026 [3]. Group 2: Company Performance - On December 17, 2025, Vistagen announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for treating social anxiety disorder did not show statistically significant improvement on the primary endpoint [3]. - Following this announcement, Vistagen's stock price dropped by $3.499 per share, representing an 80.25% decline, closing at $0.861 per share [4].